Prevention of cytotoxic T cell escape using a heteroclitic subdominant viral T cell determinant

PLoS Pathogens

Volumn 4, Issue 10, 2008, Pages

  Butler, Noah S ^a   Theodossis, Alex ^b   Webb, Andrew I ^c   Nastovska, Roza ^c   Ramarathinam, Sri Harsha ^c   Dunstone, Michelle A ^b   Rossjohn, Jamie ^b   Purcell, Anthony W ^c   Perlman, Stanley ^a  

^a UNIVERSITY OF IOWA   (United States)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; PEPTIDE; H2 ANTIGEN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL FUNCTION; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXIC T LYMPHOCYTE; HEPATITIS VIRUS; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PROTEIN MOTIF; PROTEIN STABILITY; ANIMAL; ANTIGEN PRESENTATION; ANTIGENIC MODULATION; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; IMMUNOLOGY; MURINE HEPATITIS CORONAVIRUS; PHYSIOLOGY; SITE DIRECTED MUTAGENESIS; TEMPERATURE; THERMODYNAMICS; VIRUS INFECTION;

MURINE HEPATITIS VIRUS; MUS;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENIC MODULATION; CORONAVIRUS INFECTIONS; EPITOPES, T-LYMPHOCYTE; H-2 ANTIGENS; IMMUNODOMINANT EPITOPES; MICE; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MURINE HEPATITIS VIRUS; MUTAGENESIS, SITE-DIRECTED; PROTEIN STABILITY; T-LYMPHOCYTES, CYTOTOXIC; TEMPERATURE; THERMODYNAMICS;

EID: 55449084894     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1000186     Document Type: Article

References (59)

1. Bowen DG, Walker CM (2005) Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man. J Exp Med 201: 1709-1714.
2. Goulder PJ, Watkins DI (2004) HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol 4: 630-640.
3. McMichael AJ, Phillips RE (1997) Escape of human immunodeficiency virus from immune control. Annu Rev Immunol 15: 271-296.
4. Oxenius A, Price DA, Trkola A, Edwards C, Gostick E, et al. (2004) Loss of viral control in early HIV-1 infection is temporally associated with sequential escape from CD8+ T cell responses and decrease in HIV-1-specific CD4+ and CD8+ T cell frequencies. J Infect Dis 190: 713-721.
5. Draenert R, Le Gall S, Pfafferott KJ, Leslie AJ, Chetty P, et al. (2004) Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J Exp Med 199: 905-915.
6. Seifert U, Liermann H, Racanelli V, Halenius A, Wiese M, et al. (2004) Hepatitis C virus mutation affects proteasomal epitope processing. J Clin Invest 114: 250-259.
7. Timm J, Lauer GM, Kavanagh DG, Sheridan I, Kim AY, et al. (2004) CD8 epitope escape and reversion in acute HCV infection. J Exp Med 200: 1593-1604.
8. Allen TM, Yu XG, Kalife ET, Reyor LL, Lichterfeld M, et al. (2005) De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection. J Virol 79: 12952-12960.
9. Turnbull EL, Lopes AR, Jones NA, Cornforth D, Newton P, et al. (2006) HIV-1 epitope-specific CD8+ T cell responses strongly associated with delayed disease progression cross-recognize epitope variants efficiently. J Immunol 176: 6130-6146.
10. Friedrich TC, Frye CA, Yant LJ, O'Connor DH, Kriewaldt NA, et al. (2004) Extraepitopic compensatory substitutions partially restore fitness to simian immunodeficiency virus variants that escape from an immunodominant cytotoxic-T-lymphocyte response. J Virol 78: 2581-2585.
11. Kelleher AD (2001) Clustered mutations in HIV-1 Gag are consistently required for escape from HLA-B27 restricted CTL responses. J Exp Med 193: 375-386.
12. Purcell AW, McCluskey J, Rossjohn J (2007) More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 6: 404-414.
13. Okazaki T, Pendleton CD, Lemonnier F, Berzofsky JA (2003) Epitope-enhanced conserved HIV-1 peptide protects HLA-A2-transgenic mice against virus expressing HIV-1 antigen. J Immunol 171: 2548-2555.
14. Okazaki T, Pendleton CD, Sarobe P, Thomas EK, Iyengar S, et al. (2006) Epitope enhancement of a CD4 HIV epitope toward the development of the next generation HIV vaccine. J Immunol 176: 3753-3759.
15. Tangri S, Ishioka GY, Huang X, Sidney J, Southwood S, et al. (2001) Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J Exp Med 194: 833-846.
16. Dyall R, Bowne WB, Weber LW, LeMaoult J, Szabo P, et al. (1998) Heteroclitic immunization induces tumor immunity. J Exp Med 188: 1553-1561.
17. Fikes JD, Sette A (2003) Design of multi-epitope, analogue-based cancer vaccines. Expert Opin Biol Ther 3: 985-993.
18. Butler NS, Dandekar AA, Perlman S (2007) Antiviral antibodies are necessary to prevent cytotoxic T-lymphocyte escape in mice infected with a coronavirus. J Virol 81: 13291-13298.
19. Butler NS, Theodossis A, Webb AI, Dunstone MA, Nastovska R, et al. (2008) Structural and biological basis of CTL escape in coronavirus-infected mice. J Immunol 180: 3926-3937.
20. Pewe L, Wu GF, Barnett EM, Castro RF, Perlman S (1996) Cytotoxic T cell-resistant variants are selected in a virus-induced demyelinating disease. Immunity 5: 253-262.
21. Castro RF, Perlman S (1995) CD8+ T-cell epitopes within the surface glycoprotein of a neurotropic coronavirus and correlation with pathogenicity. J Virol 69: 8127-8131.
22. Kim TS, Perlman S (2003) Protection against CTL escape and clinical disease in a murine model of virus persistence. J Immunol 171: 2006-2013.
23. Webb AI, Dunstone MA, Chen W, Aguilar MI, Chen Q, et al. (2004) Functional and structural characteristics of NY-ESO-1-related HLA A2-restricted epitopes and the design of a novel immunogenic analogue. J Biol Chem 279: 23438-23446.
24. Falk K, Rötzschke O, Stevanovic S, Jung G, Rammensee H-G (1991) Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351: 290-296.
25. van Bleek GM, Nathenson SG (1991) The structure of the antigen-binding groove of major histocompatibility complex class I molecules determines specific selection of self- peptides. Proc Natl Acad Sci U S A 88: 11032-11036.
26. Mannering SI, Harrison LC, Williamson NA, Morris JS, Thearle DJ, et al. (2005) The insulin A-chain epitope recognized by human T cells is posttranslationally modified. J Exp Med 202: 1191-1197.
27. Perlman S, Schelper R, Bolger E, Ries D (1987) Late onset, symptomatic, demyelinating encephalomyelitis in mice infected with MHV-JHM in the presence of maternal antibody. Microb Pathog 2: 185-194.
28. Wu GF, Dandekar AA, Pewe L, Perlman S (2000) CD4 and CD8 T cells have redundant but not identical roles in virus-induced demyelination. J Immunol 165: 2278-2286.
29. Dandekar AA, Jacobsen G, Waldschmidt TJ, Perlman S (2003) Antibody-mediated protection against cytotoxic T-cell escape in coronavirus-induced demyelination. J Virol 77: 11867-11874.
30. Pewe L, Xue S, Perlman S (1997) Cytotoxic T-cell-resistant variants arise at early times after infection in C57BL/6 but not in SCID mice infected with a neurotropic coronavirus. J Virol 71: 7640-7647.
31. Pewe L, Perlman S (1999) Immune response to the immunodominant epitope of mouse hepatitis virus is polyclonal, but functionally monospecific in C57Bl/6 mice. Virology 255: 106-116.
32. Weiss SR, Navas-Martin S (2005) Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev 69: 635-664.
33. Anghelina D, Pewe L, Perlman S (2006) Pathogenic role for virus-specific CD4 T cells in mice with coronavirus-induced acute encephalitis. Am J Pathol 169: 209-222.
34. Stohlman SA, Hinton DR, Parra B, Atkinson R, Bergmann CC (2007) CD4 T cells contribute to virus control and pathology following CNS infection by neurotropic mouse hepatitis virus. J Virol.
35. Pewe LL, Netland JM, Heard SB, Perlman S (2004) Very diverse CD8 T cell clonotypic responses after virus infections. J Immunol 172: 3151-3156.
36. Chen JL, Stewart-Jones G, Bossi G, Lissin NM, Wooldridge L, et al. (2005) Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J Exp Med 201: 1243-1255.
37. Alexander-Miller MA, Leggatt GR, Berzofsky JA (1996) Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci U S A 93: 4102-4107.
38. Bullock TN, Mullins DW, Engelhard VH (2003) Antigen density presented by dendritic cells in vivo differentially affects the number and avidity of primary, memory, and recall CD8(+) T cells. J Immunol 170: 1822-1829.
39. Rubio V, Stuge TB, Singh N, Betts MR, Weber JS, et al. (2003) Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med 9: 1377-1382.
40. Boon AC, de Mutsert G, Fouchier RA, Osterhaus AD, Rimmelzwaan GF (2006) The hypervariable immunodominant NP418-426 epitope from the influenza A virus nucleoprotein is recognized by cytotoxic T lymphocytes with high functional avidity. J Virol 80: 6024-6032.
41. Lauer GM, Ouchi K, Chung RT, Nguyen TN, Day CL, et al. (2002) Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol 76: 6104-6113.
42. Leslie A, Price DA, Mkhize P, Bishop K, Rathod A, et al. (2006) Differential selection pressure exerted on HIV by CTL targeting identical epitopes but restricted by distinct HLA alleles from the same HLA supertype. J Immunol 177: 4699-4708.
43. Erickson AL, Kimura Y, Igarashi S, Eichelberger J, Houghton M, et al. (2001) The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 15: 883-895.
44. Moskophidis D, Zinkernagel RM (1995) Immunobiology of cytotoxic T-cell escape mutants of lymphocytic choriomeningitis virus. J Virol 69: 2187-2193.
45. Price GE, Ou R, Jiang H, Huang L, Moskophidis D (2000) Viral escape by selection of cytotoxic T cell-resistant variants in influenza A virus pneumonia. J Exp Med 191: 1853-1867.
46. Tester I, Smyk-Pearson S, Wang P, Wertheimer A, Yao E, et al. (2005) Immune evasion versus recovery after acute hepatitis C virus infection from a shared source. J Exp Med 201: 1725-1731.
47. Pircher H, Moskophidis D, Rohrer U, Burki K, Hengartner H, et al. (1990) Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo. Nature 346: 629-633.
48. Kuo L, Godeke GJ, Raamsman MJ, Masters PS, Rottier PJ (2000) Retargeting of coronavirus by substitution of the spike glycoprotein ectodomain: crossing the host cell species barrier. J Virol 74: 1393-1406.
49. Ontiveros E, Kuo L, Masters PS, Perlman S (2001) Inactivation of expression of gene 4 of mouse hepatitis virus strain JHM does not affect virulence in the murine CNS. Virology 289: 230-238.
50. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, et al. (2005) Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 7: 413-421.
51. Hamilton SE, Harty JT (2002) Quantitation of CD8+ T cell expansion, memory, and protective immunity after immunization with peptide-coated dendritic cells. J Immunol 169: 4936-4944.
52. Leslie AGW (1992) Recent changes to the MOSFLM package for processing film and image plate data. In Joint CCP4 + ESF-EAMCB Newsletter on Protein Crystallography. Warrington: Daresbury Laboratory.
53. Evans PR (1993) Data reduction. In Proceedings of the CCP4 study weekend. Data collection and processing. In: Sawyer L, Isaacs NW, Bailey S, eds. Warrington: Daresbury Laboratory. pp 114-122.
54. Storoni LC, McCoy AJ, Read RJ (2004) Likelihood-enhanced fast rotation functions. Acta Crystallogr D Biol Crystallogr 60: 432-438.
55. Afonine PV, Grosse-Kunstleve RW, Adams PD (2005) A robust bulk-solvent correction and anisotropic scaling procedure. Acta Crystallographica Section D 61: 850-855.
56. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53: 240-255.
57. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132.
58. Lamzin VS, Wilson KS (1993) Automated refinement of protein models. Acta Crystallographica Section D 49: 129-147.
59. Williams RK, Jiang GS, Holmes KV (1991) Receptor for mouse hepatitis virus is a member of the carcinoembryonic antigen family of glycoproteins. Proc Natl Acad Sci U S A 88: 5533-5536.